Researchers in the United Kingdom are launching an initiative to develop miniature human organs and tissues grown from cells obtained through the NHS. These structures, known as organoids, will be used to advance pharmaceutical testing and decrease reliance on animal models in drug development.
The organoids are designed to help scientists understand how diseases manifest differently across patient populations, enabling them to determine which treatments prove most effective for specific individuals based on underlying disease characteristics. This represents a departure from traditional animal testing approaches toward methods grounded directly in human biological systems. Organoids, which are tissue clusters smaller than a millimetre, have demonstrated the ability to replicate key features of full organs, including disease progression and responses to pharmaceuticals.
Historically, more than 90 percent of drugs that successfully pass animal testing have subsequently failed during human trials, prompting regulatory bodies in the United States and Europe to support alternative testing methodologies when available. The research initiative will operate from a Cambridge hub supported by £20m in funding from the Medical Research Council. Scientists will develop a standardized library of validated organoids to be made available to both academic institutions and pharmaceutical companies.
The program aligns with a government strategy to accelerate the reduction of animals used in research through new approach methodologies, including organoids, organ-on-chip systems, and artificial intelligence applications. Initial efforts will focus on organoids for inflammatory bowel diseases, cancer research, and neurological conditions. Additional funding of £2m from Innovate UK supports nine projects targeting reduction of animals such as dogs and monkeys in safety testing, with some companies developing alternatives like heart cells grown in gel spheres to replace traditional animal-based toxicity assessments.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI